{
    "nctId": "NCT00785213",
    "officialTitle": "An Open-Label Drug-Drug Interaction Study to Investigate the Effects of Steady State Quinine on the Single-Dose Pharmacokinetics of Rosiglitazone Maleate in Healthy Volunteers",
    "inclusionCriteria": "* Healthy adults 18-45 years of age\n* Non-smoking\n* Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures)\n* Body mass index (BMI) less than or equal to 32\n* Medically healthy on the basis of medical history and physical examination\n* Hemoglobin \\> or = to 11.5g/dL\n* Completion of the screening process within 28 days prior to dosing\n* Provision of voluntary written informed consent\n* Must have minimum age of 18 Years\n* Must have maximum age of 45 Years",
    "exclusionCriteria": "* Recent participation (within 28 days) in other research studies\n* Recent significant blood donation or plasma donation\n* Pregnant or lactating\n* Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)\n* Recent (2-year) history or evidence of alcoholism or drug abuse\n* History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease\n* Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study\n* Drug allergies to quinine sulfate or rosiglitazone"
}